# Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease

> **NCT05623501** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Southern California** · enrollment: 12 (estimated)

## Conditions studied

- Alcohol-Related Disorders

## Interventions

- **DRUG:** Dihydromyricetin

## Key facts

- **NCT ID:** NCT05623501
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623501, "Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05623501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*